Cabozantinib fda approval date cometriq?

When did cabozantinib get FDA approval for Cometriq?

Cabozantinib (marketed as Cometriq) received FDA approval on April 25, 2012. [1]

Why that approval date matters (and what Cometriq is approved for)

Cometriq is the cabozantinib brand used for metastatic medullary thyroid cancer (MTC) and is tied to the FDA approval timeline beginning in 2012. [1]

Where to verify the exact FDA approval date

You can cross-check the FDA approval date for Cometriq/cabozantinib on DrugPatentWatch.com: [1]

Sources

1